J&J says Darzalex, Carvykti drive Q1 pharma sales growth while medtech looms large
Johnson & Johnson released its first quarter financial report Monday morning, highlighting a sales growth of 2.3% to $21.4 billion and touting an 8.3% growth in worldwide innovative medicine sales driven by Darzalex and Carvykti, among others.
Sales of its cancer drug Darzalex hit $2.69 billion for the quarter and was ahead of most consensus, with $1.4 billion coming from the US and $1.22 billion in the rest of the world, according to a press release from licensing partner Genmab.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.